Fig. 4
Readministration of ALK-TKIs in patients following re-biopsy. The outer layer is subsequent TKI drugs for patients with ALK-resistant mutations (n = 22). And the inner layer is subsequent TKI drugs for patients without ALK-resistant mutations (n = 13)